Related references
Note: Only part of the references are listed.Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
Elisa Rumi et al.
BLOOD (2017)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations
Umberto Gianelli et al.
MODERN PATHOLOGY (2017)
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Guilin Tang et al.
HAEMATOLOGICA (2017)
Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms
A. F. Sandes et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2017)
Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology
Paola Guglielmelli et al.
LEUKEMIA RESEARCH (2017)
Myeloproliferative Neoplasms
Jerry L. Spivak
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Myeloproliferative Neoplasms
Tiziano Barbui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data
Martin Schalling et al.
BLOOD CANCER JOURNAL (2017)
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Guilin Tang et al.
HAEMATOLOGICA (2017)
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia
Hans Michael Kvasnicka et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease
Georg Jeryczynski et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
Florian Zink et al.
BLOOD (2017)
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
Paola Guglielmelli et al.
BLOOD (2017)
Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version
Alessandra Iurlo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
Jelena D. Milosevic Feenstra et al.
BLOOD (2016)
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients
Xenia Cabagnols et al.
BLOOD (2016)
Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes
Alberto Alvarez-Larran et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study
Hans Michael Kvasnicka et al.
HISTOPATHOLOGY (2016)
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
H. Gisslinger et al.
LEUKEMIA (2016)
Laboratory Investigation of Myeloproliferative Neoplasms (MPNs)
Lambert Busque et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2016)
LNK mutations and myeloproliferative disorders
Mary Frances McMullin et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Myeloproliferative neoplasms: Morphology and clinical practice
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances
T. Barbui et al.
BLOOD REVIEWS (2016)
Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing
A. Pardanani et al.
LEUKEMIA (2016)
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified
Sa A. Wang et al.
MODERN PATHOLOGY (2016)
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
V. De Stefano et al.
BLOOD CANCER JOURNAL (2016)
Targeted deep sequencing in primary myelofibrosis
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
WHO classification 2008 of myeloproliferative neoplasms: a workshop learning effect - the Danish experience
Ann B. Madelung et al.
APMIS (2015)
The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading
O. Pozdnyakova et al.
LEUKEMIA (2015)
The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis
T. Barbui et al.
LEUKEMIA (2015)
Masked polycythemia Vera (mPV): Results of an international study
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Circulating hematopoietic progenitor cells in essential thrombocythemia versus prefibrotic/early primary myelofibrosis
Klaus Geissler et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter
Giovanni Barosi
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Giada Rotunno et al.
BLOOD (2014)
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Elisa Rumi et al.
BLOOD (2014)
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
Ayalew Tefferi et al.
BLOOD (2014)
Presence of calreticulin mutations in JAK2-negative polycythemia vera
Julien Broseus et al.
BLOOD (2014)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
John T. Reilly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes
Alberto Alvarez-Larran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera
Federico Lussana et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Calreticulin mutations and long-term survival in essential thrombocythemia
A. Tefferi et al.
LEUKEMIA (2014)
Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper
Giovanni Barosi et al.
LEUKEMIA RESEARCH (2014)
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Mingchao Xie et al.
NATURE MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms
Umberto Gianelli et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
World Health Organization-defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations-The Danish experience
Ann Brinch Madelung et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis
Richard T. Silver et al.
BLOOD (2013)
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
Heinz Gisslinger et al.
BLOOD (2013)
Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up
Elisabeth Ejerblad et al.
HEMATOLOGY (2013)
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia
A. Pardanani et al.
LEUKEMIA (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
Julia E. Maxson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update
Hans Michael Kvasnicka
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia
Alessandra Carobbio et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Brief report Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
Tiziano Barbui et al.
BLOOD (2012)
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
G. Finazzi et al.
LEUKEMIA (2012)
Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis
Giovanni Barosi et al.
PLOS ONE (2012)
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification
Juergen Thiele et al.
BLOOD (2011)
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
Francesco Passamonti et al.
BLOOD (2011)
The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera
Khadija Abdulkarim et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis
Maud Brousseau et al.
HISTOPATHOLOGY (2010)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Etiology and Outcome of Extreme Leukocytosis in 758 Nonhematologic Cancer Patients A Retrospective, Single-Institution Study
John M. Granger et al.
CANCER (2009)
The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the early prepolycythemic phase of polycythemia vera and essential thrombocythemia
Umberto Gianelli et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis
Claudia Vener et al.
BLOOD (2008)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis
A. Traverse-Glehen et al.
LEUKEMIA (2007)
Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation
Kais Hussein et al.
BLOOD (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology
Umberto Gianelli et al.
LEUKEMIA & LYMPHOMA (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera
Hans Michael Kvasnicka et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Grade of bone marrow fibrosis is associated with relevant hematological findings - a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis
J Thiele et al.
ANNALS OF HEMATOLOGY (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Bone marrow biopsy morbidity: review of 2003
BJ Bain
JOURNAL OF CLINICAL PATHOLOGY (2005)
Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia
J Thiele et al.
ACTA HAEMATOLOGICA (2005)
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin
F Ding et al.
BLOOD (2004)
Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients
J Thiele et al.
PATHOLOGY RESEARCH AND PRACTICE (2001)
Share Paper
